Page 18 - EASL Recommendations on Treatment of Hepatitis C 2015 - Summary
P. 18
Table 4C. Drug-drug interactions between Table 4D. Drug-drug interactions between
HCV DAAs and lipid lowering drugs. HCV DAAs and central nervous system
drugs.
SIM DCV SOF SOF/ 3D SIM DCV SOF SOF/ 3D
LDV LDV
Atorvastatin ••••• Amitriptyline ••• ••
Bezafibrate Citalopram
Ezetimibe ••••• Duloxetine ••• ••
Fenofibrate Escitalopram
Fluvastatin ••••• Fluoxetine ••• ••
Gemfibrozil Paroxetine
Lovastatin ••••• Anti-depressants Sertraline ••• ••
Pitavastatin Trazodone
Pravastatin ••••• Trimipramine
Rosuvastatin Venlafaxine
Simvastatin ••••• Amisulpiride ••• ••
Aripiprazole
••••• Chlorpromazine ••• ••
Clozapine
••••• Flupentixol ••• ••
Haloperidol
••••• Olanzapine ••• ••
Quetiapine
••••• Risperidone ••• ••
••••• ••• ••
••• ••
••• ••
SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV, Anti-psychotics ••• ••
sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir,
plus ombitasvir and dasabuvir. ••• ••
Colour legend. Green: No clinically significant interaction
expected. Amber: Potential interaction which may require a ••• ••
dosage adjustment, altered timing of administration or additional
monitoring. Red: These drugs should not be co-administered. ••• ••
o Some drugs may require dose modifications ••• ••
dependent on hepatic function. Please refer to the
product label for individual drugs for dosing advice. ••• ••
o The symbol (green, amber, red) used to rank the ••• ••
clinical significance of the drug interaction is based on
www.hep-druginteractions.org SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV,
(University of Liverpool). For additional drug-drug sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir,
interactions and for a more extensive range of drugs, plus ombitasvir and dasabuvir.
detailed pharmacokinetic interaction data and dosage Colour legend. Green: No clinically significant interaction
expected. Amber: Potential interaction which may require a
adjustments, refer to the above-mentioned website. dosage adjustment, altered timing of administration or additional
monitoring. Red: These drugs should not be co-administered.
o Some drugs may require dose modifications
dependent on hepatic function. Please refer to the
product label for individual drugs for dosing advice.
o The symbol (green, amber, red) used to rank the
clinical significance of the drug interaction is based on
www.hep-druginteractions.org
(University of Liverpool). For additional drug-drug
interactions and for a more extensive range of drugs,
detailed pharmacokinetic interaction data and dosage
adjustments, refer to the above-mentioned website.
17
HCV DAAs and lipid lowering drugs. HCV DAAs and central nervous system
drugs.
SIM DCV SOF SOF/ 3D SIM DCV SOF SOF/ 3D
LDV LDV
Atorvastatin ••••• Amitriptyline ••• ••
Bezafibrate Citalopram
Ezetimibe ••••• Duloxetine ••• ••
Fenofibrate Escitalopram
Fluvastatin ••••• Fluoxetine ••• ••
Gemfibrozil Paroxetine
Lovastatin ••••• Anti-depressants Sertraline ••• ••
Pitavastatin Trazodone
Pravastatin ••••• Trimipramine
Rosuvastatin Venlafaxine
Simvastatin ••••• Amisulpiride ••• ••
Aripiprazole
••••• Chlorpromazine ••• ••
Clozapine
••••• Flupentixol ••• ••
Haloperidol
••••• Olanzapine ••• ••
Quetiapine
••••• Risperidone ••• ••
••••• ••• ••
••• ••
••• ••
SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV, Anti-psychotics ••• ••
sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir,
plus ombitasvir and dasabuvir. ••• ••
Colour legend. Green: No clinically significant interaction
expected. Amber: Potential interaction which may require a ••• ••
dosage adjustment, altered timing of administration or additional
monitoring. Red: These drugs should not be co-administered. ••• ••
o Some drugs may require dose modifications ••• ••
dependent on hepatic function. Please refer to the
product label for individual drugs for dosing advice. ••• ••
o The symbol (green, amber, red) used to rank the ••• ••
clinical significance of the drug interaction is based on
www.hep-druginteractions.org SIM, simeprevir; DCV, daclatasvir; SOF, sofosbuvir; SOF/LDV,
(University of Liverpool). For additional drug-drug sofosbuvir plus ledipasvir; 3D, ritonavir-boosted paritaprevir,
interactions and for a more extensive range of drugs, plus ombitasvir and dasabuvir.
detailed pharmacokinetic interaction data and dosage Colour legend. Green: No clinically significant interaction
expected. Amber: Potential interaction which may require a
adjustments, refer to the above-mentioned website. dosage adjustment, altered timing of administration or additional
monitoring. Red: These drugs should not be co-administered.
o Some drugs may require dose modifications
dependent on hepatic function. Please refer to the
product label for individual drugs for dosing advice.
o The symbol (green, amber, red) used to rank the
clinical significance of the drug interaction is based on
www.hep-druginteractions.org
(University of Liverpool). For additional drug-drug
interactions and for a more extensive range of drugs,
detailed pharmacokinetic interaction data and dosage
adjustments, refer to the above-mentioned website.
17
